Idera Pharmaceuticals,Inc. (NASDAQ:IDRA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On December14, 2018,Idera Pharmaceuticals,Inc. (the “Company”) issued an investor presentation relating to data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, the Company’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*). The investor presentation is furnished as Exhibit99.1 and is incorporated herein by reference.
The Company is furnishing the information in this Item 7.01 and the related Exhibit99.1 filed herewith to comply with Regulation FD. Such information shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing. This Item 7.01 will not be deemed an admission as to the materiality of any information herein (including Exhibit99.1) that is required to be disclosed solely by Regulation FD.
Item 8.01 Other Events.
On December14, 2018, the Company issued a press release in connection with the data described in Item 7.01. The press release is furnished as Exhibit99.2 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
See the ExhibitIndex below, which is incorporated by reference herein.
IDERA PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a18-41620_1ex99d1.htm EX-99.1 Exhibit 99.1 Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 2 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,…
To view the full exhibit click here
About Idera Pharmaceuticals,Inc. (NASDAQ:IDRA)
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company’s TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.
